Key result
Elevated serum MMP-9 levels in the acute phase of ischemic stroke were associated with a significantly increased risk of post-stroke depression at 3 months (OR 4.36 for the highest vs. lowest quartile).
Why the study?
Matrix metalloproteinase-9 might cause cerebral damage after stroke and contribute to depressive symptoms, but its association with post-stroke depression required evaluation.
Does elevated serum MMP-9 in the acute phase of ischemic stroke predict post-stroke depression at 3 months?
Cohort (n=558)
Yes
Does elevated serum MMP-9 in the acute phase of ischemic stroke predict post-stroke depression at 3 months?
Odds Ratio: 4.36 (95% CI 2.49–7.65)
Absolute Event Rate: 55.7% vs 25.4%
p-value: p=<0.001
Elevated serum MMP-9 levels in the acute phase of ischemic stroke are strongly associated with an increased risk of developing depression at 3 months, suggesting its potential as a prognostic biomarker.
May aid early post-stroke depression risk stratification; leaves open causal role and clinical utility pending validation.
No takes yet. Share an insight, caveat, or question.
Che et al. (2019) conducted a cohort in Acute ischemic stroke (n=558). Serum Matrix Metalloproteinase-9 (MMP-9) vs. Lowest quartile of serum MMP-9 (<330.1 ng/mL) was evaluated on Post-stroke depression (PSD) at 3 months (HRSD-24 score ≥ 8) (OR 4.36, 95% CI 2.49-7.65, p=<0.001). Elevated serum MMP-9 levels in the acute phase of ischemic stroke were associated with a significantly increased risk of post-stroke depression at 3 months (OR 4.36 for the highest vs. lowest quartile).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: